RGEN
Repligen Corporation
NASDAQ: RGEN · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$115.91
-3.35% today
Updated 2026-06-05
Market cap
$6.99B
P/E ratio
137.72
P/S ratio
8.36x
EPS (TTM)
$0.90
Dividend yield
—
52W range
$101 – $176
Volume
1.1M
WallStSmart proprietary scores
49
out of 100
Grade: C
Sell
Investment rating
6.0
Growth
B8.0
Quality
A4.5
Profitability
C4.0
Valuation
C4/9
Piotroski F-Score
Moderate
2.5
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$178.74
+54.21%
12-Month target
$40.25
-65.27%
Intrinsic (DCF)
$155.38
Margin of safety
+10.28%
3 Strong Buy14 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $23.35M — positive
+ Revenue growth 14.80% QoQ
+ 10.28% below intrinsic value
+ Debt/equity 0.33x — low leverage
Risks
- P/E 137.72x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $801.54M | $638.76M | $634.44M | $738.26M | $763.34M |
| Net income | $185.96M | $41.58M | $-25.51M | $48.89M | $8.33M |
| EPS | — | — | — | — | $0.90 |
| Free cash flow | $38.74M | $74.93M | $142.49M | $93.90M | $23.35M |
| Profit margin | 23.20% | 6.51% | -4.02% | 6.62% | 6.73% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-05 | LOEILLOT, OLIVIER | Buy | 25,890 | — |
| 2026-03-05 | LOEILLOT, OLIVIER | Buy | 24,134 | — |
| 2026-03-05 | KURIYEL, RALF | Buy | 5,669 | — |
Peer comparison
Smart narrative
Repligen Corporation trades at $115.91. representing a P/E of 137.72x trailing earnings. Our Smart Value Score of 49/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.47, it sits in the grey zone. TTM revenue stands at $763.34M. with profit margins at 6.73%. Our DCF model estimates intrinsic value at $155.38.
Frequently asked questions
What is Repligen Corporation's stock price?
Repligen Corporation (RGEN) trades at $115.91, on a P/E of 137.7x and a P/S of 8.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Repligen Corporation overvalued?
Repligen Corporation carries a Smart Value Score of 49/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $155.38 versus the $115.91 price, a 10.3% margin of safety on a cash flow basis.
What is the price target of Repligen Corporation (RGEN)?
The 12-month analyst consensus target is $178.74, about 54.2% above the current $115.91. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Repligen Corporation (RGEN)?
Our DCF model estimates intrinsic value at $155.38, a +10.3% margin of safety versus today's $115.91. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Repligen Corporation's revenue?
Repligen Corporation's trailing twelve-month revenue is $763.34M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Repligen Corporation's Altman Z-Score is 2.47, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio8.36x
ROE2.44%
Beta1.09
50D MA$117.99
200D MA$137.82
Shares out0.06B
Float0.05B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—